前哨淋巴结
纳米技术
材料科学
生物医学工程
医学
乳腺癌
癌症
内科学
作者
Binge Deng,Yan Wang,Xiangdong Bu,Jin Li,Jingsong Lu,Li Lin,Yaohui Wang,Yao Chen,Jian Ye
出处
期刊:Biomaterials
[Elsevier BV]
日期:2024-03-27
卷期号:308: 122538-122538
被引量:16
标识
DOI:10.1016/j.biomaterials.2024.122538
摘要
Surface-enhanced Raman spectroscopy (SERS) nanotags have garnered much attention as promising bioimaging contrast agent with ultrahigh sensitivity, but their clinical translation faces challenges including biological and laser safety. As breast sentinel lymph node (SLN) imaging agents, SERS nanotags used by local injection and only accumulation in SLNs, which were removed during surgery, greatly reduce biological safety concerns. But their clinical translation lacks pilot demonstration on large animals close to humans. The laser safety requires irradiance below the maximum permissible exposure threshold, which is currently not achievable in most SERS applications. Here we report the invention of the core-shell SERS nanotags with ultrahigh brightness (1 pM limit of detection) at the second near-infrared (NIR-II) window for SLN identification on pre-clinical animal models including rabbits and non-human primate. We for the first time realize the intraoperative SERS-guided SLN navigation under a clinically safe laser (1.73 J/cm2) and identify multiple axillary SLNs on a non-human primate. No evidence of biosafety issues was observed in systematic examinations of these nanotags. Our study unveils the potential of NIR-II SERS nanotags as appropriate SLN tracers, making significant advances toward the accurate positioning of lesions using the SERS-based tracer technique.
科研通智能强力驱动
Strongly Powered by AbleSci AI